menu
    • menu
    [{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Series A Financing","leadProduct":"212Pb-DOTAMTATE","moa":"Alpha radiation","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"RadioMedix \/ Portland Investment Counsel Inc.","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Portland Investment Counsel Inc."},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Alphamedix","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"212Pb-DOTAMTATE","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RadioMedix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RadioMedix \/ Oranomed","highestDevelopmentStatusID":"8","companyTruncated":"RadioMedix \/ Oranomed"},{"orgOrder":0,"company":"Oranomed","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"212Pb-DOTAMTATE","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Oranomed","amount2":0.35999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Oranomed \/ Sanofi","highestDevelopmentStatusID":"14","companyTruncated":"Oranomed \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for Alphamedix

    Menu

    Alphamedix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oranomed

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Oranomed

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $357.1 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sanofi, RadioMedix, Orano Med Announce Agreement on Radioligand Medicine for Cancers

                            Details : Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano will manufacture AlphaMedix through its global industrial platform currently under development.

                            Brand Name : AlphaMedix

                            Molecule Type : Peptide

                            Upfront Cash : $111.6 million

                            September 12, 2024

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $357.1 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Receive Breakthrough Designation for AlphaMedixTM

                            Details : AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy for unresectable, metastatic gastroenteropancreatic neuroendocrine tumors, naïve to peptide receptor therapy.

                            Brand Name : AlphaMedix

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 12, 2024

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oranomed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in ...

                            Details : AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitt...

                            Brand Name : AlphaMedix

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 16, 2023

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oranomed

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            RadioMedix

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Plat...

                            Details : The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuro...

                            Brand Name : AlphaMedix

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 07, 2022

                            Lead Product(s) : Alphamedix

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Portland Investment Counsel Inc.

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth